Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application
Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application
复制标题
DOI：
10.1016/j.peptides.2005.09.016
复制
发表时间：
2006-04-01
期刊：
影响因子：
3
通讯作者：
Grote, JJ
中科院分区：
文献类型：
--
作者：
Nell, MJ;Tjabringa, GS;Grote, JJ
开发了用于中和上呼吸道感染中的脂多糖（LPS）和脂磷壁酸（LTA）的新肽，并就应用于人类的功效和安全性进行了评价。基于人抗微生物肽LL-37的序列，我们开发并研究了长度变体、取代类似物和修饰以稳定肽，从而防止酶促降解并提高功效。最有希望的肽出现P60.4，这是一种24个氨基酸的肽，在LPS和LTA中和和较低的促炎活性方面具有与LL-37相似的功效。此外，与LL-37相比，该肽的乙酰化和酰胺化形式显示出无毒性并且显示出更高或相等的抗微生物活性。(c)2005年爱思唯尔公司All rights reserved.
New peptides for lipopolysaccharide (LPS) and lipoteichoic acid (LTA) neutralization in upper respiratory tract infections were developed and evaluated in terms of efficacy and safety for application in humans. Based on the sequence of the human antimicrobial peptide LL-37 we developed and investigated length variants, substitution analogues and modifications to stabilize the peptides to prevent enzymatic degradation and to improve efficacy. The most promising peptide appears P60.4, a 24 amino acid peptide with similar efficacy as LL-37 in terms of LPS and LTA neutralization and lower pro-inflammatory activity. In addition, the acetylated and amidated version of this peptide shows no toxicity and displays higher or equal antimicrobial activity compared to LL-37. (c) 2005 Elsevier Inc. All rights reserved.